Methylation of forkhead box protein 3 gene promoter in CD4+ T cells in patients with chronic hepatitis B
10.3760/cma.j.issn.1003-9279.2018.01.007
- VernacularTitle: 慢性乙型肝炎患者CD4＋T细胞Foxp3基因甲基化状态的研究
- Author:
Jun ZHANG
1
;
Feng LI
1
;
Yuchen FAN
2
;
Jing ZHAO
1
;
Haiming LI
1
;
Xinyuan LIU
1
;
Mingming TIAN
1
;
Shuai GAO
1
;
Yanbo YU
3
;
Kai WANG
2
Author Information
1. Department of Hepatology, Qilu Hospital of Shandong University, Jinan 250012, China
2. Department of Hepatology, Qilu Hospital of Shandong University, Jinan 250012, China; Institute of Hepatology, Shandong University, Jinan 250012, China
3. Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China
- Publication Type:Journal Article
- Keywords:
Forkhead box protein 3;
methylation;
chronic hepatitis B;
CD4+ 25+ Foxp3+ regulatory T cells
- From:
Chinese Journal of Experimental and Clinical Virology
2018;32(1):32-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the methylation status and expression of FOXP3 in CD4+ T cells of patients with chronic hepatitis B (CHB).
Methods:Peripheral blood mononuclear cells (PBMCs) from 59 CHB patients and 22 healthy controls (HC) were collected. The percentage of CD4+ CD25+ Foxp3+ Tregs in CD4+ T cells was estimated by flow cytometry. FOXP3 expression was measured by quantitative real time-polymerase chain reaction (RT-qPCR) and Western blotting. The methylation status of FOXP3 was determined by methylation-specific polymerase chain reaction.
Results:The percentage of CD4+ CD25+ pFoxp3+ Tregs in CD4+ T cells, FOXP3 mRNA and protein expression levels were significantly higher in patients with CHB than HCs (P<0.05). Meanwhile, the methylation frequency of FOXP3 was significantly lower in CHB patients than HCs (P<0.05). FOXP3 mRNA levels and the percentage of CD4+ CD25+ Foxp3+ Tregs were significantly lower (P<0.05) in patients with gene methylation than those without.
Conclusions:Aberrant demethylation of FOXP3 gene existed in CD4+ T cells of CHB, which contributed to an elevation in FOXP3 expression and percentage of CD4+ CD25+ Foxp3+ Tregs. It might provide a new target for prevention and treatment of CHB.
